Physicians' Academy for Cardiovascular Education
A systematic review and meta-analysis showed higher Lp(a) levels were associated with the onset, progression, and serious adverse outcomes of calcific aortic valve disease, particularly in younger individuals and male-dominant populations.
ESC Congress 2023 How do healthy lifestyle interventions fit in the current therapeutic landscape for patients with established CVD? Nadia Bonekamp interviews Ruxandra Maria Christodorescu about this topic.
"What is hypertriglyceridemia? We have to think particles", says Erik Stroes. In this video, he explains the relationship between triglyceride-risk lipoproteins and atherogenic risk.
In an observational cohort study, higher plasma levels of eicosapentaenoic acid (EPA), but not docosahexaenoic acid (DHA), were associated with a lower 10-year risk of MACE. Adjustment for DHA level increased the protective effect of higher EPA levels.
A prespecified substudy of the PACMAN-AMI trial showed 1 year of alirocumab, on top of rosuvastatin, resulted in regression of the angiographic diameter stenosis of non-obstructive coronary lesions in acute MI patients, compared with an increase with placebo.
Despite the use of statins for LDL-c lowering, there remains a residual risk in patients with high CV risk. Stephen Nicholls talks about recommendations in guidelines and real world clinical practice.
According to the latest registries, the majority of high- and very high-risk patients do not accieve 2019 ESC/EAS recommended LDL-c goals. Kausik Ray discusses how LDL-c goal attainment can be improved.
ESC Congress 2023 Pascal Burger presents the results of a subanalysis of the REDUCE-IT trial, which examined the treatment effects of icosapent ethyl in subgroups with different 5-year residual CV risks.
ESC Congress 2023 The ESC guidelines for NSTE-ACS and STEMI have been combined in one document, as different presentations of ACS are all part of one spectrum, explains Borja Ibáñez. He discusses the highlights of the new guidelines on the management of ACS.
ESC Congress 2023 In a phase 1 trial, daily administration of the oral small molecule muvalaplin for 14 days lowered Lp(a) levels up to 65%, with no safety or tolerability concerns.
ESC Congress 2023 Investigators of the phase 3 LIBerate-HeFH trial reported data on the efficacy and safety of the small PCSK9 binding protein lerodalcibep in patients with heterozygous FH (HeFH).
ESC Congress 2023 The ORION-8 trial, an open-label extension of ORION-3/9/10/11, demonstrated the efficacy, safety and tolerability of inclisiran in patients with high cardiovascular risk and elevated LDL-c.
